Epidemiology & Real-World Evidence of SUL-DUR in Special Populations with CRAB Infection
Epidemiology & Real-World Evidence of SUL-DUR in Special Populations with CRAB Infection funds researchers studying CRAB and SUL-DUR in adult patient groups in China to assess disease burden and treatment outcomes.
Funder: Pfizer Inc.
Due Dates: February 3, 2027 (Submission deadline, 23:59 EST)
Funding Amounts: Up to $58,200 per project for up to 1 year; 3 awards
Summary: Supports research on CRAB epidemiology and the real-world effectiveness, safety, and treatment timing of sulbactam-durlobactam in special adult populations in mainland China.
Key Information: Both the institution and principal investigator must be based in mainland China.
Description
Pfizer’s competitive research grant program supports studies characterizing the epidemiology and clinical burden of carbapenem-resistant Acinetobacter baumannii (CRAB) infections in mainland China. It also seeks real-world evidence on the effectiveness and safety of sulbactam-durlobactam (SUL-DUR) in routine clinical practice among critically ill adults with suspected or confirmed CRAB infections.
The program focuses on postoperative neurosurgical patients, liver or kidney transplant recipients, and burn patients. Research interests include treatment patterns, the impact of SUL-DUR initiation timing, clinical success, microbiological success, mortality, and adverse events. Pfizer selects projects through an internal review process. Grantees retain responsibility for the design, implementation, sponsorship, and conduct of their independent research.
